Results 191 to 200 of about 48,857 (215)

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade

open access: yesAdvanced Science, EarlyView.
This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou   +12 more
wiley   +1 more source

Regulation of dendrite growth and maintenance by exocytosis.

open access: yesJ Cell Sci, 2015
Peng Y   +8 more
europepmc   +1 more source

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

open access: yesAdvanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun   +15 more
wiley   +1 more source

Mechanically driven Li dendrite penetration in garnet solid electrolyte. [PDF]

open access: yesNature
Zhang Y   +14 more
europepmc   +1 more source

Stochastic growth and ligand-receptor interaction-mediated stabilization generate stereotyped dendritic arbors. [PDF]

open access: yesNat Neurosci
Shi R   +10 more
europepmc   +1 more source

Advanced Design of Three-Dimensional Lithiophilic Carbon-Based Hosts for Anode-Free Lithium Metal Batteries. [PDF]

open access: yesNanomicro Lett
Yang F   +9 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Home - About - Disclaimer - Privacy